Christina  Willwerth net worth and biography

Christina Willwerth Biography and Net Worth

Ms. Willwerth has more than 25 years of experience in pharmaceutical development. Most recently, Ms. Willwerth served as Flexion’s Senior Vice President of Program Management and Strategy, and in her expanded role she continues to lead the planning and execution of our strategic vision and business priorities and have accountability for Flexion’s portfolio development efforts and Human Resources activities. Ms. Willwerth joined Flexion Therapeutics from Viacell, where she was a member of the company’s Executive Management team and served as Vice President, Product Development, with management responsibility for the company’s interdisciplinary cellular therapy and fertility preservation development programs. She previously served as Senior Director, Product Development at The Medicines Company, where she focused on cardiovascular therapy clinical and product development. Prior to that, she held a number of ascendant clinical operations positions at Astra Pharmaceuticals and Biopure Corporation. Ms. Willwerth holds a B.S. in Biology, with high distinction, from Worcester Polytechnic Institute

What is Christina Willwerth's net worth?

The estimated net worth of Christina Willwerth is at least $1.22 million as of July 19th, 2021. Ms. Willwerth owns 133,486 shares of Flexion Therapeutics stock worth more than $1,217,392 as of March 28th. This net worth approximation does not reflect any other assets that Ms. Willwerth may own. Learn More about Christina Willwerth's net worth.

How do I contact Christina Willwerth?

The corporate mailing address for Ms. Willwerth and other Flexion Therapeutics executives is 10 MALL ROAD SUITE 301, BURLINGTON MA, 01803. Flexion Therapeutics can also be reached via phone at (781) 305-7777 and via email at [email protected]. Learn More on Christina Willwerth's contact information.

Has Christina Willwerth been buying or selling shares of Flexion Therapeutics?

Christina Willwerth has not been actively trading shares of Flexion Therapeutics during the past quarter. Most recently, Christina Willwerth sold 3,945 shares of the business's stock in a transaction on Monday, July 19th. The shares were sold at an average price of $6.45, for a transaction totalling $25,445.25. Following the completion of the sale, the insider now directly owns 133,486 shares of the company's stock, valued at $860,984.70. Learn More on Christina Willwerth's trading history.

Who are Flexion Therapeutics' active insiders?

Flexion Therapeutics' insider roster includes David Arkowitz (CFO), and Christina Willwerth (Insider). Learn More on Flexion Therapeutics' active insiders.

Christina Willwerth Insider Trading History at Flexion Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/19/2021Sell3,945$6.45$25,445.25133,486View SEC Filing Icon  
See Full Table

Christina Willwerth Buying and Selling Activity at Flexion Therapeutics

This chart shows Christina Willwerth's buying and selling at Flexion Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Flexion Therapeutics Company Overview

Flexion Therapeutics logo
Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA.
Read More

Today's Range

Now: $9.12
Low: $9.12
High: $9.12

50 Day Range

MA: $9.20
Low: $9.12
High: $9.44

2 Week Range

Now: $9.12
Low: $4.30
High: $13.66

Volume

N/A

Average Volume

1,177,479 shs

Market Capitalization

$458.93 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.53